Suppressive effects of antimycotics on tumor necrosis factor-α-induced CCL27, CCL2, and CCL5 production in human keratinocytes

Biochemical Pharmacology

Volumn 72, Issue 4, 2006, Pages 463-473

  Kanda, Naoko ^a   Watanabe, Shinichi ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antimycotic; CCL2; CCL27; CCL5; Keratinocyte; Prostaglandin E2

Indexed keywords

ANTIFUNGAL AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTISERUM; CCL27 CHEMOKINE; CHEMOKINE; FLUCONAZOLE; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KETOCONAZOLE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN H2; PROSTAGLANDIN INHIBITOR; RANTES; RECEPTOR SUBUNIT; TERBINAFINE; THROMBOXANE A2; THROMBOXANE B2; THROMBOXANE SYNTHASE; THROMBOXANE SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; INFLAMMATORY INFILTRATE; INHIBITION KINETICS; KERATINOCYTE; METABOLITE; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; PSORIASIS VULGARIS;

ANTIFUNGAL AGENTS; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINES; CHEMOKINES, CC; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HUMANS; KERATINOCYTES; KETOCONAZOLE; MALE; NAPHTHALENES; NF-KAPPA B; OLIGONUCLEOTIDES, ANTISENSE; RECEPTORS, PROSTAGLANDIN E; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THROMBOXANE A2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745935754     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.05.001     Document Type: Article

References (53)

1. Giustizieri M.L., Mascia F., Frezzolini A., De Pita O., Chinni L.M., Giannetti A., et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 107 (2001) 871-877
2. Morales J., Homey B., Vicari A.P., Hudak S., Oldham E., Hedrick J., et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci USA 96 (1999) 14470-14475
3. Homey B., Alenius H., Muller A., Soto H., Bowman E.P., Yuan W., et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 8 (2002) 157-165
4. Kanda N., and Watanabe S. 17β-estradiol inhibits the production of RANTES in human keratinocytes. J Invest Dermatol 120 (2003) 420-427
5. Yamada H., Matsukura M., Yudate T., Chihara J., Stingl G., and Tezuka T. Enhanced production of RANTES, an eosinophil chemoattractant factor, by cytokine-stimulated epidermal keratinocytes. Int Arch Allergy Immunol 114 Suppl 1 (1997) 28-32
6. Kanda N., and Watanabe S. 17β-estradiol inhibits MCP-1 production in human keratinocytes. J Invest Dermatol 120 (2003) 1058-1066
7. Vestergaard C., Johansen C., Otkjaer K., Deleuran M., and Iversen L. Tumor necrosis factor-alpha-induced CTACK/CCL27 (cutaneous T-cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor kappa B. Cytokine 29 (2005) 49-55
8. 2 suppresses CCL27 production through EP2 and EP3 receptors in human keratinocytes. J Allergy Clin Immunol 114 (2004) 1403-1409
9. Ciesielski C.J., Andreakos E., Foxwell B.M., and Feldmann M. TNF-α-induced macrophage chemokine secretion is more dependent on NF-κB expression than lipopolysaccharide-induced macrophage chemokine secretion. Eur J Immunol 32 (2002) 2037-2045
10. Dwarakanath R.S., Sahar S., Reddy M.A., Castanotto D., Rossi J.J., and Natarajan R. Regulation of monocyte chemoattractant protein-1 by the oxidized lipid, 13-hydroperoxyoctadecadienoic acid, in vascular smooth muscle cells via nuclear factor-κB (NF-κB). J Mol Cell Cardiol 36 (2004) 585-595
11. Tzanakakis G.N., Krambovitis E., Tsatsakis A.M., and Vezeridis M.P. The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis. Int J Gastrointest Cancer 32 (2002) 23-30
12. Back O., Scheynius A., and Johansson S.G. Ketoconazole in atopic dermatitis: therapeutic response is correlated with decrease in serum IgE. Arch Dermatol Res 287 (1995) 448-451
13. Broberg A., and Faergemann J. Topical antimycotic treatment of atopic dermatitis in the head/neck area. A double-blind randomized study. Acta Dermatol Venereol 75 (1995) 46-49
14. Farr P.M., Krause L.B., Marks J.M., and Shuster S. Response of scalp psoriasis to oral ketoconazole. Lancet 26-2 8461 (1985) 921-922
15. Nikkels A.F., and Pierard G.E. Framing the future of antifungals in atopic dermatitis. Dermatology 206 (2003) 398-400
16. Sugita T., Tajima M., Ito T., Saito M., Tsuboi R., and Nishikawa A. Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species. J Clin Microbiol 43 (2005) 2824-2829
17. Gupta A.K., Batra R., Bluhm R., Boekhout T., and Dawson Jr. T.L. Skin diseases associated with Malassezia species. J Am Acad Dermatol 51 (2004) 785-798
18. Tengvall Linder M., Johansson C., Scheynius A., and Wahlgren C. Positive atopy patch test reactions to Pityrosporum orbiculare in atopic dermatitis patients. Clin Exp Allergy 30 (2000) 122-131
19. Baroni A., Paoletti I., Ruocco E., Agozzino M., Tufano M.A., and Donnarumma G. Possible role of Malassezia furfur in psoriasis: modulation of TGF-β1, integrin, and HSP70 expression in human keratinocytes and in the skin of psoriasis-affected patients. J Cutan Pathol 31 (2004) 35-42
20. Boyman O., Conrad C., Dudli C., Kielhorn E., Nickoloff B.J., and Nestle F.O. Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis. Br J Dermatol 152 (2005) 1211-1218
21. Kanda N., Enomoto U., and Watanabe S. Antimycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis. J Invest Dermatol 117 (2001) 1635-1646
22. Kanda N., and Watanabe S. Ketoconazole suppresses interleukin-4 plus anti-CD40-induced IgE class switching in surface IgE negative B cells from patients with atopic dermatitis. J Invest Dermatol 119 (2002) 590-599
23. Niczyporuk W., Krajewska-Kulak E., and Zimnoch L. Preliminary study on the effect of the selected calmodulin antagonists on the skin. Rocz Akad Med Bialymst 41 (1996) 515-524
24. Kanda N., Koike S., and Watanabe S. IL-17 suppresses TNF-α-induced CCL27 production through induction of COX-2 in human keratinocytes. J Allergy Clin Immunol 116 (2005) 1144-1150
25. Su J.L., Shih J.Y., Yen M.L., Jeng Y.M., Chang C.C., Hsieh C.Y., et al. Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res 64 (2004) 554-564
26. 2-induced cAMP production and sensitization of sensory neurons. J Biol Chem 276 (2001) 16083-16091
27. 2 in nonadherent human monocytes. J Immunol 158 (1997) 351-358
28. Saklatvala J., Rawlinson L., Waller R.J., Sarsfield S., Lee J.C., Morton L.F., et al. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J Biol Chem 271 (1996) 6586-6589
29. Takada Y., Fang X., Jamaluddin M.S., Boyd D.D., and Aggarwal B.B. Genetic deletion of glycogen synthase kinase-3β abrogates activation of IκBα kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 279 (2004) 39541-39554
30. Pary G.C., and Mackman N. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-κB-mediated transcription. J Immunol 159 (1997) 5450-5456
31. Delgado M., and Ganea D. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor κB-dependent transcriptional activity. Biochem Biophys Res Commun 302 (2003) 275-283
32. Neumann M., Grieshammer T., Chuvpilo S., Kneitz B., Lohoff M., Schimpl A., et al. RelA/p65 is a molecular target for the immunosuppressive action of protein kinase A. EMBO J 14 (1995) 1991-2004
33. Alexanian A.R., and Bamburg J.R. Neuronal survival activity of S100ββ is enhanced by calcineurin inhibitors and requires activation of NF-κB. FASEB J 13 (1999) 1611-1620
34. 2+-dependent signal transduction pathways. J Immunol 155 (1995) 4685-4691
35. Tolman E.L., and Fuller B.L. Inhibition of thromboxane synthesis in guinea pig lung and human platelets by clotrimazole and other imidazole antifungals. Biochem Pharmacol 32 (1983) 3488-3490
36. Culo F., Renic M., Sabolovic D., Rados M., Bilic A., and Jagic V. Ketoconazole inhibits acetaminophen-induced hepatotoxicity in mice. Eur J Gastroenterol Hepatol 7 (1995) 757-762
37. Chevalier D., Lo-Guidice J.M., Sergent E., Allorge D., Debuysere H., Ferrari N., et al. Identification of genetic variants in the human thromboxane synthase gene (CYP5A1). Mutat Res 432 (2001) 61-67
38. Wachter G.A., Hartmann R.W., Sergejew T., Grun G.L., and Ledergerber D. Tetrahydronaphthalenes: influence of heterocyclic substituents on inhibition of steroid enzymes P450 arom and P450 17. J Med Chem 39 (1996) 834-841
39. Vanden Bossche H., Marichal P., Gorrens J., and Coene M.C. Biochemical basis for the activity and selectivity of oral antifungal drugs. Br J Clin Pract Suppl 71 (1990) 41-46
40. Higashi Y., Omura M., Suzuki K., Inano H., and Oshima H. Ketoconazole as a possible universal inhibitor of cytochrome P-450 dependent enzymes: its mode of inhibition. Endocrinol Jpn 34 (1987) 105-115
41. Hsu P.Y., Tsai A.L., Kulmacz R.J., and Wang L.H. Expression, purification, and spectroscopic characterization of human thromboxane synthase. J Biol Chem 274 (1999) 762-769
42. Hecker M., Haurand M., Ullrich V., and Terao S. Spectral studies on structure-activity relationships of thromboxane synthase inhibitors. Eur J Biochem 157 (1986) 217-223
43. Cupp-Vickery J.R., Garcia C., Hofacre A., and McGee-Estrada K. Ketoconazole-induced conformational changes in the active site of cytochrome P450eryF. J Mol Biol 311 (2001) 101-110
44. Ryder N.S. The mechanism of action of terbinafine. Clin Exp Dermatol 14 (1989) 98-100
45. Madani S., Barilla D., Cramer J., Wang Y., and Paul C. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol 42 (2002) 1211-1218
46. Debruyne D., and Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet 40 (2001) 441-472
47. Matsuura K., Yoshioka S., Tosha T., Hori H., Ishimori K., Kitagawa T., et al. Structural diversities of active site in clinical azole-bound forms between sterol 14α-demethylases (CYP51s) from human and Mycobacterium tuberculosis. J Biol Chem 280 (2005) 9088-9096
48. 2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275 (2000) 32783-32792
49. Li X., Afif H., Cheng S., Martel-Pelletier J., Pelletier J.P., Ranger P., et al. Expression and regulation of microsomal prostaglandin E synthase-1 in human osteoarthritic cartilage and chondrocytes. J Rheumatol 32 (2005) 887-895
50. 2 synthase gene. Essential role of the transcription factor Egr-1. J Biol Chem 277 (2002) 28601-28608
51. Yucel-Lindberg T., Hallstrom T., Kats A., Mustafa M., and Modeer T. Induction of microsomal prostaglandin E synthase-1 in human gingival fibroblasts. Inflammation 28 (2004) 89-95
52. Chin T.W., Loeb M., and Fong I.W. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother 39 (1995) 1671-1675
53. Jensen J.C. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 14 (1989) 110-113